EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

From silos to synergy: the interdisciplinary discovery potential in redefining polyendocrine metabolic ovarian syndrome

Michaela M Morhaus, Lauren W Yowelunh McLester-Davis, Judith A Simcox

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci209199 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Michaela M Morhaus und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metabolic Syndrome. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polyendocrine metabolic ovarian syndrome (PMOS) affects one of every eight women worldwide and is associated with high rates of cardiovascular disease, type 2 diabetes, and infertility. Polycystic ovarian syndrome (PCOS), another term for this condition, reflects a historical focus on its effects on the female reproductive system. Recently, however, experts and patient groups have advocated renaming the condition PMOS, conveying increasing recognition that hyperandrogenism and insulin resistance contribute to its pathology. In this issue, Nguyen et al. took a systems genetic approach that combined data from murine models of PMOS and data from human studies, identifying the splicing factor 3b subunit 1 (SF3B1) and IGFBP2, both previously associated with metabolic disease, as molecular drivers of PMOS. SF3B1 inhibitors improved PMOS symptoms in mice, including decreased adiposity, hypoandrogenism, and insulin levels. These findings open therapeutic and mechanistic avenues in the study of PMOS, including exploration of splice variants as regulators of disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeMetabolic SyndromeFemaleHumansAnimalsMiceRNA Splicing FactorsInsulin ResistanceHyperandrogenismPhosphoproteinsDisease Models, Animal

Substanzen

RNA Splicing FactorsPhosphoproteins

Autor:innen und Institutionen

  • Department of Biochemistry and.
  • Cell Molecular Biology Program, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Medical Scientist Training Program, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Howard Hughes Medical Institute, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Förderung

  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS

Zitieren

APA

Morhaus, M. M., McLester-Davis, L. W. Y., & Simcox, J. A. (2026). From silos to synergy: the interdisciplinary discovery potential in redefining polyendocrine metabolic ovarian syndrome. Journal of Clinical Investigation. https://doi.org/10.1172/jci209199

Vancouver

Morhaus MM, McLester-Davis LWY, Simcox JA. From silos to synergy: the interdisciplinary discovery potential in redefining polyendocrine metabolic ovarian syndrome. Journal of Clinical Investigation. 2026. doi:10.1172/jci209199

BibTeX
@article{Morhaus2026,
  author = {Morhaus, Michaela M and McLester-Davis, Lauren W Yowelunh and Simcox, Judith A},
  title = {From silos to synergy: the interdisciplinary discovery potential in redefining polyendocrine metabolic ovarian syndrome},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci209199}
}
Kostenlos starten →